People: Ligand Pharmaceuticals Inc (LGND.OQ)
LGND.OQ on NASDAQ Stock Exchange Global Market
49.02USD
1 Aug 2013
49.02USD
1 Aug 2013
Price Change (% chg)
$1.64 (+3.46%)
$1.64 (+3.46%)
Prev Close
$47.38
$47.38
Open
$48.04
$48.04
Day's High
$50.39
$50.39
Day's Low
$46.85
$46.85
Volume
62,857
62,857
Avg. Vol
77,473
77,473
52-wk High
$50.77
$50.77
52-wk Low
$14.77
$14.77
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Kozarich |
62 | 2007 | Independent Chairman of the Board |
John Higgins |
42 | 2007 | President, Chief Executive Officer, Director |
John Sharp |
47 | 2007 | Chief Financial Officer, Vice President - Finance |
Matthew Foehr |
39 | 2011 | Chief Operating Officer, Executive Vice President |
Charles Berkman |
43 | 2007 | Vice President, General Counsel, Secretary |
Nishan de Silva |
39 | 2012 | Vice President - Corporate Development |
Jason Aryeh |
44 | 2006 | Independent Director |
Todd Davis |
51 | 2007 | Independent Director |
David Knott |
68 | 2007 | Independent Director |
John LaMattina |
62 | 2011 | Independent Director |
Sunil Patel |
40 | 2010 | Independent Director |
Stephen Sabba |
52 | 2008 | Independent Director |
Erika Luib |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
John Kozarich |
Dr. John W. Kozarich, Ph.D., serves as an Independent Chairman of the Board of Ligand Pharmaceuticals Inc. He served as a member of the company board of directors since March 2003. Dr. Kozarich is chairman and president and a director of ActivX Biosciences, Inc., which he joined in January 2001. ActivX is a wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd., Tokyo, Japan. From 1992 to 2001, Dr. Kozarich was vice president at Merck Research Laboratories, where he was responsible for a number of research programs. Dr. Kozarich is also a biotechnology professor at the Scripps Research Institute, and previously held faculty positions at the University of Maryland and Yale University School of Medicine. Dr. Kozarich earned his B.S. in chemistry from Boston College (summa cum laude; ÖBK), his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH postdoctoral fellow at Harvard University. In selecting Dr. Kozarich to serve as a director, the board considered, among other things, his pharmaceutical and international experience, including his service at Merck Research Laboratories, which is part of one of the world’s pharmaceutical companies and his service as Chief Executive Officer of ActivX Biosciences, Inc., a subsidiary of a Japan-based, international pharmaceutical company. |
John Higgins |
Mr. John L. Higgins serves as President,Chief Executive Officer, Director of Ligand Pharmaceuticals Inc. He joined the Company in January 2007 as President and Chief Executive Officer and he was also appointed to the Board in March 2007. Prior to joining the Company, Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics since January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Currently, he is a Director of BioCryst and serves as Chairperson of its audit committee. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and serves on the board, audit and compensation committees of Techne Corporation, a company with a market capitalization of over $2 billion. Mr. Higgins has served as a director of numerous public and private companies. He graduated Magna Cum Laude with an A.B. from Colgate University. In selecting Mr. Higgins to serve as a director, the board considered, among other things, his experience operating and managing public biotechnology companies, including his service on the boards of other biopharmaceutical companies and his financial transaction experience as an investment banker. |
John Sharp |
Mr. John P. Sharp, CPA., serves as Chief Financial Officer, Vice President - Finance of Ligand Pharmaceuticals Inc. He joined the Company in April 2007 as our Vice President, Finance and Chief Financial Officer. From November 2004 to April 2007, Mr. Sharp served as Vice President of Finance of Sequenom, Inc. and served as its Principal Accounting Officer since October 2005. From August 2000 to November 2004, Mr. Sharp served as Director of Accounting at Diversa Corporation, a publicly traded biotech company. From January 1994 until August 2000, Mr. Sharp was at the public accounting firm PricewaterhouseCoopers (formerly Coopers & Lybrand), most recently as a Senior Audit Manager. He received a B.S. from San Diego State University, and is a certified public accountant (inactive) and a member of the Association of BioScience Financial Officers. |
Matthew Foehr |
Mr. Matthew W. Foehr serves as Chief Operating Officer, Executive Vice President of Ligand Pharmaceuticals Inc., since April 18, 2011. Mr. Foehr has more than 17 years of experience managing global research and development programs. Prior to joining the Company, commencing in January 2010, he was Vice President and Head of Consumer Dermatology R&D, as well as Interim Chief Scientific Officer of Dermatology commencing in 2010, in the Stiefel division of GlaxoSmithKline (GSK), where he was responsible for the global R&D consumer dermatology franchise, heading all R&D strategy and operations for the business. Following GSK’s $3.6 billion acquisition of Stiefel Laboratories, Inc. (Stiefel) in December 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. Prior to GSK’s acquisition, Mr. Foehr served as Senior Vice President of Global R&D Operations for Stiefel from April 2009 through December 2009, Senior Vice President of Product Development & Support from March 2009 to April 2009, and Vice President of Supply Chain Technical Services from January 2007 to March 2008. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation from July 1999 through December 2006, including a position as Senior Vice President of Technical Operations and Vice President of Manufacturing from January 2003 through December 2006. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. Mr. Foehr received his B.S. in biology from Santa Clara University. |
Charles Berkman |
Mr. Charles S. Berkman J.D., serves as Vice President, General Counsel, Secretary of Ligand Pharmaceuticals Inc., since April 2007. Mr. Berkman joined the Company in November 2001 and previously served as Associate General Counsel and Chief Patent Counsel for the Company (and Secretary since March 2007). Prior to joining the Company, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law. |
Nishan de Silva |
Dr. Nishan de Silva, M.D., M.B.A., serves as Vice President - Corporate Development of Ligand Pharmaceuticals Inc. He joined the Company in February 2012 as our Vice President of Corporate Development. Nishan has more than twelve years of healthcare experience across healthcare investing and management consulting. Prior to joining Ligand, Dr. de Silva served as a Principal of private equity firm Warburg Pincus LLC, where he was responsible for sourcing late-stage biopharmaceutical investments. Over the previous eight years, he evaluated hundreds of biopharmaceutical company investment opportunities, negotiated and structured equity positions for several companies and served on the board of directors for several public and private biopharmaceutical companies. Prior to joining Warburg Pincus, Dr. de Silva worked in healthcare venture capital at Sprout Group and as a management consultant at McKinsey & Company, where he focused on growth strategy projects for senior management at global pharmaceutical and healthcare services companies. Dr. de Silva holds an M.D. from The University of Pennsylvania School of Medicine, an M.B.A. in Healthcare Management from The Wharton School, and an A.B. in Biology from Harvard College. |
Jason Aryeh |
Mr. Jason M. Aryeh serves as an Independent Director of Ligand Pharmaceuticals Inc., since September 2006. He is the founder and managing general partner of JALAA Equities, LP, a private hedge fund focused on the biotechnology and specialty pharmaceutical sector, and has served in such capacity since 1997. Mr. Aryeh also serves on the board of directors of Nabi Biopharmaceuticals, a public biotechnology company, CorMatrix Cardiovascular, a medical device company, Myrexis, Inc., a public biotechnology company, and the Cystic Fibrosis Foundation’s Therapeutics Board (CFFT). Mr. Aryeh earned an A.B. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics. In selecting Mr. Aryeh to serve as a director, the board considered, among other things, his capital markets experience, including his prior service as managing general partner of a hedge fund focused on the biotechnology and specialty pharmaceutical sector. |
Todd Davis |
Mr. Todd C. Davis serves as an Independent Director of Ligand Pharmaceuticals Inc., since March 2007. Since December 2006, Mr. Davis has served as a managing director of Cowen Healthcare Royalty Management, LLC, the investment advisor to Cowen Healthcare Royalty Partners, L.P. Previously, from November 2004 to October 2006, Mr. Davis served as a partner at Paul Capital Partners, an investment firm. From 2001 to 2004, Mr. Davis served as a partner at Apax Partners. Mr. Davis has historically been employed in the health care industry in positions at Abbott Laboratories and Elan. Mr. Davis has historically served on the boards of several public and private companies, including Artes Medical, Inc., and currently serves on the board of Suneva Medical, Inc. Mr. Davis earned a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard Business School. |
David Knott |
Mr. David M. Knott serves as an Independent Director of Ligand Pharmaceuticals Inc., since March 2007. Since 1987, Mr. Knott has served as chief investment manager of Knott Partners Management and Dorset Management, two related hedge fund entities. From 1983 to 1987, he served as general partner and analyst at Mandrakos Associates. Prior to that, Mr. Knott was a broker at Donaldson Lufkin & Jenrette (DLJ). Mr. Knott currently serves on the board of directors of Paramount Resources. He received a B.A. in political science from the University of Pennsylvania and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. |
John LaMattina |
Dr. John L. LaMattina, Ph.D., serves as an Independent Director of Ligand Pharmaceuticals Inc., since February 7, 2012. He spent 30 years at Pfizer Inc. retiring as president of Pfizer Global R&D at the end of 2007. During his career, he held various positions of responsibility, including Vice President of U.S. Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999. Dr. LaMattina graduated with cum laude honors from Boston College with a B.S. in Chemistry. He received a Ph.D. from the University of New Hampshire in Organic Chemistry and subsequently was at Princeton University in the National Institutes of Health Postdoctoral Fellowship program. Dr. LaMattina is currently a senior partner at PureTech, a venture capital firm focusing on biotech investments, and serves on several boards, including the Board of Human Genome Science, Inc., the Board of Trustees of Boston College and the Scientific Advisory Board for Trevena Pharmaceuticals. |
Sunil Patel |
Mr. Sunil Patel serves as an Independent Director of Ligand Pharmaceuticals Inc., since October 7, 2010. Mr. Patel has more than 17 years of senior management and R&D experience in the biotechnology industry and is currently Senior Vice President of Corporate Development for OncoMed Pharmaceuticals, a development-stage company focused on therapeutics targeting cancer stem cells. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Allos Therapeutics, Connetics, Abgenix and Gilead Sciences. Mr. Patel also worked at McKinsey & Company serving biotech and pharmaceutical clients and has held scientific research positions at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master’s degree in Molecular Bioengineering/Biotechnology at the University of Washington. |
Stephen Sabba |
Dr. Stephen L. Sabba, M.D., serves as an Independent Director of Ligand Pharmaceuticals Inc., August 4, 2008. Dr. Sabba has been a leading Research Analyst and Bio Fund Manager for Knott Partners Management, an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza’s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Memorial Hospital in North Tarrytown, New York. He received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a Bachelor of Science degree with honors from Cornell University. |
Erika Luib |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Kozarich |
-- |
John Higgins |
1,633,160 |
John Sharp |
596,999 |
Matthew Foehr |
1,493,620 |
Charles Berkman |
478,873 |
Nishan de Silva |
-- |
Jason Aryeh |
-- |
Todd Davis |
-- |
David Knott |
-- |
John LaMattina |
-- |
Sunil Patel |
-- |
Stephen Sabba |
-- |
Erika Luib |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
John Kozarich |
0 | 0 |
John Higgins |
0 | 0 |
John Sharp |
0 | 0 |
Matthew Foehr |
0 | 0 |
Charles Berkman |
0 | 0 |
Nishan de Silva |
0 | 0 |
Jason Aryeh |
0 | 0 |
Todd Davis |
0 | 0 |
David Knott |
0 | 0 |
John LaMattina |
0 | 0 |
Sunil Patel |
0 | 0 |
Stephen Sabba |
0 | 0 |
Erika Luib |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DE SILVA NISHAN M |
169 | $17.36 |
FOEHR MATTHEW W |
1,059 | $17.36 |
BERKMAN CHARLES S |
815 | $17.36 |
LAMATTINA JOHN L |
2,925 | $0.00 |
DAVIS TODD C |
2,925 | $0.00 |
SABBA STEPHEN L |
3,621 | $0.00 |
ARYEH JASON M |
2,925 | $0.00 |
LAMATTINA JOHN L |
696 | $0.00 |
PATEL SUNIL |
1,393 | $0.00 |
KNOTT DAVID M |
4,318 | $0.00 |
PATEL SUNIL |
2,925 | $0.00 |
KOZARICH JOHN W |
2,925 | $0.00 |
KOZARICH JOHN W |
1,393 | $0.00 |
DAVIS TODD C |
1,393 | $0.00 |
HIGGINS JOHN L |
12,000 | $0.00 |
FOEHR MATTHEW W |
8,333 | $0.00 |
BERKMAN CHARLES S |
4,000 | $26.66 |
HIGGINS JOHN L |
8,000 | $0.00 |
FOEHR MATTHEW W |
6,000 | $0.00 |
BERKMAN CHARLES S |
2,500 | $0.00 |
DE SILVA NISHAN M |
5,000 | $0.00 |
SHARP JOHN P |
2,500 | $0.00 |
BVF PARTNERS L P |
39,600 | $19.78 |
DE SILVA NISHAN M |
490 | $14.54 |
KOZARICH JOHN W |
3,333 | $12.06 |

